|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2017
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EF02
|
|
gptkbp:brand
|
gptkb:Kisqali
|
|
gptkbp:CASNumber
|
1211441-98-3
|
|
gptkbp:chemicalFormula
|
C23H30N8O
|
|
gptkbp:combines
|
gptkb:fulvestrant
aromatase inhibitors
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
CDK4/6 inhibitor
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
gptkb:ribociclib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kisqali
|
|
gptkbp:indication
|
hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
inhibits cyclin-dependent kinases 4 and 6
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
alopecia
QT prolongation
neutropenia
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:ribociclib
|
|
gptkbp:bfsLayer
|
7
|